PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3028% below fair value
$16.94+1.18 (+7.49%)
Close on Nov 18, 2026Market cap $2.35BP/E –Yield 6.85%
Perrigo operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Perrigo's operating income for the twelve months ending Jun 27, 2026 was -$1.56B, down 644.9% year over year. For fiscal 2025 it was -$1.12B, down 1094.0% from the year before. The highest annual figure on record is $679.10M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.12B | -1094.0% |
| FY2024 | Dec 31, 2024 | $112.90M | -25.7% |
| FY2023 | Dec 31, 2023 | $151.90M | +92.5% |
| FY2022 | Dec 31, 2022 | $78.90M | -80.8% |
| FY2021 | Dec 31, 2021 | $410.40M | +54.8% |
| FY2020 | Dec 31, 2020 | $265.20M | +51.8% |
| FY2019 | Dec 31, 2019 | $174.70M | -26.1% |
| FY2018 | Dec 31, 2018 | $236.50M | -60.5% |
| FY2017 | Dec 31, 2017 | $598.20M | -11.0% |
| FY2015 | Jun 27, 2015 | $672.50M | +17.7% |
| FY2014 | Jun 28, 2014 | $571.40M | -15.9% |
| FY2013 | Jun 29, 2013 | $679.10M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $23.50M | -48.2% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | -$372.30M | -893.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$1.29B | -1227.1% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $72.60M | -9.7% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $45.40M | – |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $46.90M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $114.20M | – |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $80.40M | +29.5% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | -$26.50M | -146.7% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | -$55.20M | -213.8% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$15.60M | -150.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $62.10M | +87.6% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $56.80M | – |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $48.50M | +123.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $31.00M | -33.6% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $33.10M | -92.4% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | -$6.90M | – |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $21.70M | -57.8% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $46.70M | +24.2% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $438.30M | +458.3% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | -$125.90M | -300.8% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $51.40M | -40.5% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $37.60M | – |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $78.50M | +44.3% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $62.70M | +14.0% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $86.40M | -15.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$37.00M | -134.4% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $54.40M | – |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $55.00M | -41.9% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $102.30M | -34.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $107.50M | -32.2% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | -$122.00M | -175.1% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $94.70M | -36.4% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $156.30M | +21.6% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $158.60M | -17.5% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $162.40M | -14.7% |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $148.80M | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $128.50M | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $192.30M | – |
| Q3 FY2015CQ1 2015 | Mar 28, 2015 | $190.40M | – |
See a number that looks wrong?